Molecular Formula | C23H27N5O2 |
Molar Mass | 405.49 |
Density | 1.32±0.1 g/cm3(Predicted) |
Boling Point | 702.0±70.0 °C(Predicted) |
Solubility | DMSO: ≥ 30 mg/mL |
pKa | 16.94±0.30(Predicted) |
Storage Condition | -20℃ |
In vitro study | Orexin receptor antagonists represent attractive targets for the development of drugs for the treatment of insomnia. IPSU binds rapidly and reaches equilibrium very quickly in binding and/or functional assays. |
In vivo study | IPSU has low blood clearance, shows high maximal blood exposure and AUC after oral dosing. It exhibits an acceptable absolute oral bioavailability and a brain/blood concentration ratio that indicated favorable brain penetration. IPSU increases sleep when dosed during the mouse active phase (lights off); IPSU induces sleep primarily by increasing NREM sleep. IPSU shows a fast onset of action, with a clear increase in total sleep time during the first hour afterdosing. The effect lasts 4-5 h, after which time the total sleep time per hour is the same as on vehicle day . |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.466 ml | 12.331 ml | 24.661 ml |
5 mM | 0.493 ml | 2.466 ml | 4.932 ml |
10 mM | 0.247 ml | 1.233 ml | 2.466 ml |
5 mM | 0.049 ml | 0.247 ml | 0.493 ml |
biological activity | IPSU is a selective, orally active and brain-permeable OX2R antagonist with a pKi value of 7.85. |
Target | pKi: 7.85 (OX2R), 6.29 (OX1R) |